BioPhia Consulting Inc.
BioPhia Home
About
The Team
Services
Media
May, 2016
June, 2016
September, 2016
November, 2016
February, 2017
March, 2017
June, 2017
Regulatory
RSS
This is the category1 description.
CDER Updates March/April 2017
6/2/2017 1:43:19 PM

 

 

Update to Guidance

Section I. Introduction

• Paragraph added describing rationale for changing timetable for required master file submissions in eCTD from 24 months to 36 months.

Section III.B. Timetable for Implementation of Electronic Submission Requirements

·         Updated to reflect that the requirement for master files to be filed electronically takes place 36 months after May 5, 2015.

Example of timetable updated to reflect actual timetable for the implementation of the electronic submissions requirement.
CBER Updates March/April 2017
6/2/2017 1:41:18 PM

 

 

 

 

The Food and Drug Administration (FDA) issued a final rule, Use of Symbols in Labeling, June 15, 2016, that became effective September 13, 2016. The final rule permits the use of symbols in all medical device labeling without adjacent explanatory text (referred to as "stand-alone symbols") if certain requirements are met. The final rule also specifies that the use of symbols, accompanied by adjacent explanatory text continues to be permitted. The final rule seeks to harmonize the U.S. device labeling requirements for symbols with international regulatory requirements.

Below is a list of resources on the use of symbols in labeling:

·         Final Rule: Use of Symbols in Labeling

·         Frequently Asked Questions

FDA Voice: Using Symbols to Convey Information in Medical Device Labeling
CDRH Updates - March/April 2017
6/2/2017 1:38:02 PM

·         Presentation (WMV - 11.4MB)

·         Printable Slides (PDF - 273KB)

·         Transcript (PDF - 155KB)

§  Presentation (WMV - 19.5MB)

§  Printable Slides (PDF - 937KB)

§  Transcript (PDF - 274KB)

§  Case Study: Using the De Novo Process to Classify and Bring to Market an Innovative, Low-to-Moderate Risk Device (PDF - 504KB)

 

SUMMARY: The Food and Drug Administration (FDA or Agency) has  identified a list of class II devices that, when finalized, will be  exempt from premarket notification requirements, subject to certain limitations. FDA is publishing this notice of that determination and requesting public comment. Submit either electronic or written comments on the notice by May 15, 2017. 

 

SUMMARY: The Food and Drug Administration (FDA or Agency) has  identified a list of class I devices that are now exempt from premarket  notification requirements, subject to certain limitations. FDA is  publishing this notice of that determination in accordance with  procedures established by the 21st Century Cures Act.
 
CDER Summary February 2017
3/3/2017 9:51:16 AM
CBER Updates January 2017
2/17/2017 2:41:52 PM

Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus; Guidance for Industry (PDF - 99KB)

We, FDA, are notifying you, blood establishments that collect blood and blood components for transfusion or further manufacture, including Source Plasma, that we have determined Ebola virus to be a transfusion-transmitted infection (TTI) under Title 21 of the Code of Federal Regulations (CFR) 630.3(l). We are also providing you with recommendations for assessing blood donor eligibility, donor deferral and blood product management in the event that an outbreak of Ebola virus disease (EVD) with widespread transmission occurs in at least one country.

 

Guidance Agenda: Guidance DocumentsCBER is Planning to Publish During Calendar Year 2017 (PDF - 25KB)

This is the list of guidance topics CBER is considering for development during Calendar Year 2017. The list includes topics that currently have no guidance associated with them, topics where updated guidance may be helpful, and topics for which CBER has already issued Level 1 drafts that may be finalized following review of public comments. We currently intend to develop guidance documents on these topics; however, the Center is neither bound by this list of topics, nor required to issue every guidance document on this list. We are not precluded from developing guidance documents on topics not on this list. This list includes guidance documents CBER issued since the August 2016 Guidance Agenda update.

 

Regenerative Advanced Therapy Designation

As described in Section 3033 of the 21st Century Cures Act, a drug is eligible for designation as a regenerative advanced therapy (RAT) if:

a.      The drug is a regenerative medicine therapy, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, except for those regulated solely under Section 361 of the Public Health Service Act and part 1271 of Title 21, Code of Federal Regulations;

b.      The drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and

c.       Preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition

 

Final Agenda: Public Workshop: Identification and Characterization of Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-Based Products (PDF - 214KB)

Public Workshop: Identification and Characterization of Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-Based Products February 8-9, 2017

 

9 items total 1  2 

<< All categories
BioPhia Home
About
The Team
Services
Media
Blog